Free Trial

Molecular Templates (MTEM) Competitors

+0.02 (+1.60%)
(As of 05/28/2024 ET)


Should you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), Wave Life Sciences (WVE), Cogent Biosciences (COGT), Merus (MRUS), Bristol-Myers Squibb (BMY), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD). These companies are all part of the "medical" sector.

Molecular Templates vs.

Bolt Biotherapeutics (NASDAQ:BOLT) and Molecular Templates (NASDAQ:MTEM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, community ranking, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

In the previous week, Bolt Biotherapeutics had 1 more articles in the media than Molecular Templates. MarketBeat recorded 4 mentions for Bolt Biotherapeutics and 3 mentions for Molecular Templates. Molecular Templates' average media sentiment score of 1.03 beat Bolt Biotherapeutics' score of 1.02 indicating that Bolt Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Bolt Biotherapeutics Positive
Molecular Templates Positive

Molecular Templates has a net margin of -57.92% compared to Molecular Templates' net margin of -556.59%. Molecular Templates' return on equity of -51.74% beat Bolt Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bolt Biotherapeutics-556.59% -51.74% -37.70%
Molecular Templates -57.92%-984.38%-56.85%

Bolt Biotherapeutics currently has a consensus target price of $3.50, indicating a potential upside of 360.04%. Given Molecular Templates' higher possible upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Molecular Templates.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bolt Biotherapeutics
0 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
Molecular Templates
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 95.5% of Molecular Templates shares are held by institutional investors. 30.9% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 13.4% of Molecular Templates shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bolt Biotherapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Molecular Templates has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.

Molecular Templates has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Molecular Templates, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bolt Biotherapeutics$7.88M3.68-$69.20M-$1.66-0.46
Molecular Templates$57.31M0.15-$8.12M-$4.32-0.29

Molecular Templates received 262 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 67.32% of users gave Molecular Templates an outperform vote while only 65.57% of users gave Bolt Biotherapeutics an outperform vote.

Bolt BiotherapeuticsOutperform Votes
Underperform Votes
Molecular TemplatesOutperform Votes
Underperform Votes


Bolt Biotherapeutics and Molecular Templates tied by winning 8 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MTEM vs. The Competition

MetricMolecular TemplatesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.36M$6.72B$5.00B$8.09B
Dividend YieldN/A2.77%2.74%3.96%
P/E Ratio-0.2922.09176.4818.43
Price / Sales0.15239.902,386.6172.31
Price / CashN/A20.5033.0728.77
Price / Book1.635.854.944.39
Net Income-$8.12M$139.81M$104.35M$213.55M
7 Day Performance-6.62%-0.82%-0.63%-0.80%
1 Month Performance-25.51%3.07%3.85%3.42%
1 Year Performance-81.59%-2.29%5.47%7.53%

Molecular Templates Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Bolt Biotherapeutics
3.1082 of 5 stars
-58.4%$30.12M$7.88M-0.48100High Trading Volume
SAB Biotherapeutics
1.9136 of 5 stars
+210.2%$25.11M$2.24M0.0057Gap Down
Wave Life Sciences
4.4264 of 5 stars
+67.8%$761.70M$113.31M-11.96266Positive News
Cogent Biosciences
1.1227 of 5 stars
-25.1%$785.91MN/A-3.31164Short Interest ↑
1.7365 of 5 stars
+164.8%$3.52B$43.95M-21.66172Analyst Forecast
High Trading Volume
Bristol-Myers Squibb
4.9501 of 5 stars
-36.6%$83.60B$45.01B-13.3034,100Analyst Revision
4.5131 of 5 stars
+38.4%$164.06B$28.19B43.6926,700Short Interest ↑
Analyst Revision
Vertex Pharmaceuticals
3.932 of 5 stars
+35.4%$117.92B$9.87B29.655,400Analyst Downgrade
Positive News
Regeneron Pharmaceuticals
3.7468 of 5 stars
Gilead Sciences
4.9517 of 5 stars
-17.1%$81.83B$27.12B182.4418,000Positive News

Related Companies and Tools

This page (NASDAQ:MTEM) was last updated on 5/29/2024 by Staff

From Our Partners